NASDAQ:BIAF bioAffinity Technologies Q1 2025 Earnings Report $7.65 -0.29 (-3.65%) As of 12:11 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast bioAffinity Technologies EPS ResultsActual EPS-$72.00Consensus EPS -$72.00Beat/MissMet ExpectationsOne Year Ago EPSN/AbioAffinity Technologies Revenue ResultsActual Revenue$1.85 millionExpected Revenue$2.11 millionBeat/MissMissed by -$255.00 thousandYoY Revenue GrowthN/AbioAffinity Technologies Announcement DetailsQuarterQ1 2025Date5/15/2025TimeBefore Market OpensConference Call DateThursday, May 15, 2025Conference Call Time9:00AM ETUpcoming EarningsbioAffinity Technologies' Q3 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) bioAffinity Technologies Earnings HeadlinesbioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual ConferenceSeptember 22 at 9:44 AM | finance.yahoo.comBioAffinity Technologies Stock Surges Following Hong Kong Patent GrantSeptember 17, 2026 | benzinga.comCongress Passes Landmark Digital Asset Law Wall Street Is WatchingThe House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial technology framework in US history. JPMorgan, Citi, Bank of America and Wells Fargo are building a shared next generation payment network targeting 2027, and the DTCC just completed its first live production trades on the new system. Senior analyst Andy Howard breaks down the asset at the center of this shift in a free report.September 24 at 1:00 AM | Awesomely (Ad)Four High-Impact Small Caps Enter the SpotlightSeptember 17, 2026 | markets.businessinsider.combioAffinity Technologies Secures Hong Kong Patent for CyPath Lung Cancer DiagnosticSeptember 17, 2026 | finance.yahoo.combioAffinity secures Hong Kong patent for CyPath LungSeptember 17, 2026 | tipranks.comSee More bioAffinity Technologies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like bioAffinity Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on bioAffinity Technologies and other key companies, straight to your email. Email Address About bioAffinity TechnologiesbioAffinity Technologies (NASDAQ:BIAF) is a biotechnology company focused on developing diagnostics and therapeutics for cancer and other serious diseases. The company’s technology uses porphyrin compounds that can selectively interact with cancer cells, supporting applications in both disease detection and treatment. Its lead diagnostic product, CyPath Lung, is a noninvasive urine-based test designed to aid in the early detection of lung cancer. The test is intended to identify cancer-related signals in urine and is being developed as an alternative or complement to existing screening and diagnostic methods. bioAffinity is also developing porphyrin-based therapeutic programs, including inhaled treatments intended to target cancer cells in the lungs. Founded in 2007 and headquartered in Albuquerque, New Mexico, the company is led by Maria Zannes, who serves as president and chief executive officer. Its products and programs remain subject to applicable clinical, regulatory, and commercialization requirements.View bioAffinity Technologies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsEnergy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI Infrastructure Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
